Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its target price boosted by BMO Capital Markets from $14.00 to $15.00 in a report published on Friday morning. The brokerage currently has a market perform rating on the biopharmaceutical company’s stock.

HALO has been the topic of several other reports. BidaskClub upgraded Halozyme Therapeutics from a hold rating to a buy rating in a research note on Friday, June 16th. Zacks Investment Research cut Halozyme Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 24th. Piper Jaffray Companies set a $20.00 price objective on Halozyme Therapeutics and gave the company a buy rating in a research note on Thursday, August 10th. Barclays PLC restated an overweight rating and set a $16.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. Finally, ValuEngine upgraded Halozyme Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $16.00.

Halozyme Therapeutics (NASDAQ:HALO) traded up 1.69% during mid-day trading on Friday, reaching $16.25. 5,824,402 shares of the company’s stock traded hands. The company has a 50 day moving average price of $12.79 and a 200-day moving average price of $13.23. Halozyme Therapeutics has a 12 month low of $8.18 and a 12 month high of $16.65. The stock’s market cap is $2.18 billion.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. During the same quarter last year, the business posted ($0.21) earnings per share. Halozyme Therapeutics’s revenue was up 1.2% on a year-over-year basis. On average, analysts anticipate that Halozyme Therapeutics will post ($0.88) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Halozyme Therapeutics, Inc. (HALO) Given New $15.00 Price Target at BMO Capital Markets” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/16/halozyme-therapeutics-inc-halo-given-new-15-00-price-target-at-bmo-capital-markets.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Halozyme Therapeutics by 4.8% during the 2nd quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock worth $148,652,000 after purchasing an additional 532,658 shares during the period. Iridian Asset Management LLC CT raised its stake in shares of Halozyme Therapeutics by 2.0% during the 2nd quarter. Iridian Asset Management LLC CT now owns 10,608,993 shares of the biopharmaceutical company’s stock worth $136,007,000 after purchasing an additional 208,605 shares during the period. Vanguard Group Inc. raised its stake in shares of Halozyme Therapeutics by 9.5% during the 2nd quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after purchasing an additional 831,654 shares during the period. BB Biotech AG raised its stake in shares of Halozyme Therapeutics by 6.7% during the 2nd quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock worth $105,961,000 after purchasing an additional 515,472 shares during the period. Finally, Senzar Asset Management LLC raised its stake in shares of Halozyme Therapeutics by 17.1% during the 2nd quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock worth $52,399,000 after purchasing an additional 597,400 shares during the period. Institutional investors own 85.08% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.